Listed by the USPTO as WELLS, LAUREN QUINLAN
Tech Center 1600 • Art Units: 1622 1625 1626 1629 1691
This examiner grants 49% of resolved cases
WELLS, LAUREN QUINLAN is a USPTO patent examiner in Tech Center 1600 and Art Unit 1622. The record includes 257 resolved cases and a 49.4% allowance rate. The median time to allowance is 1120 days. Interviews show a 59.7% lift, making them a significant strategic option where applicants can present a clear amendment path. A lower baseline allowance result increases the value of identifying the examiner's central concern before filing a final response.
The leading companies are Bristol-Myers Squibb Company, University of Florida Research Foundation Inc., and Compass Pathfinder Limited. The leading firms are BALLARD SPAHR LLP, Jones Day, and Leason Ellis LLP. The company mix reflects pharmaceutical and research-oriented work. Practitioners should combine detailed technical and scientific support with interview preparation that distinguishes the claimed invention from the cited references.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18835859 | SMALL MOLECULES CXCR4 AGONISTS, METHOD OF SYNTHESIS, AND METHOD OF USE | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 18003431 | HISTONE-ACETYLATION-MODULATING AGENTS FOR THE TREATMENT AND PREVENTION OF ORGAN INJURY | Final Rejection | The Regents of the University of Michigan |
| 18718477 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18026704 | DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES | Final Rejection | Bristol-Myers Squibb Company |
| 18859397 | SOLID FORM OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3- FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9- TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL TARTRATE | Non-Final OA | Genentech, Inc. |
| 18720716 | COMPOSITIONS COMPRISING UROLITHIN FOR TREATING MUSCLE DECLINE AND A KIDNEY DYSFUNCTION | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18903075 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Non-Final OA | Vanderbilt University |
| 17588104 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | Final Rejection | The Trustees of Columbia University in the City of New York |
| 18834032 | METHOD FOR INACTIVATING VIRUSES OR BACTERIA | Non-Final OA | Kao Corporation |
| 19023946 | Benzodiazepine Pyrazolo Carboxamides as N-protein Inhibitors | Non-Final OA | Pfizer Inc. |
| 19027734 | SPIRO COMPOUND AND APPLICATION THEREOF | Non-Final OA | HITGEN INC. |
| 18480145 | COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING POLY-y-GLUTAMIC ACID ISOLATED FROM BACILLUS AS ACTIVE INGREDIENT | Final Rejection | PUKYONG NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION |
| 18571684 | BACTERIOCHLORINS WITH BETA-PYRROLE LINKER | Non-Final OA | NIRvana Sciences Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy49.4% of resolved applications examined by Lauren Quinlan Wells were allowed (257 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.
This examiner's interview lift is +59.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Lauren Quinlan Wells took 1,120 days on average from filing to allowance.
Lauren Quinlan Wells examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
